The Centers for Medicare & Medicaid Services (CMS) has certified ReWalk Robotics, Ltd., as a Medicare provider for its ReWalk Personal Exoskeleton, a robotic medical device used to increase mobility for individuals with lower limb disabilities. The certification means that the company can bill Medicare directly for procurement of the device for Medicare beneficiaries. The certification was effective as of October 20, 2020, for the majority of U.S. states. The company anticipates gaining certification in the remaining states.
In July 2020, CMS issued a Healthcare Common Procedure Coding System (HCPCS) Level II Code K1007 for the ReWalk 6.0 Exoskeleton system. The code became effective on October 1, 2020. for the majority of U.S. states. The company anticipates gaining certification in the remaining states.
As the HCPCS code goes into effect, ReWalk will pursue in-network status with private insurance companies. This will open access to individuals who do not have out-of-network Durable Medical Equipment benefits and/or those who have high out of pocket costs with out-of-network provider organizations.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the United States, Israel, and Germany.
This was reported by ReWalk Robotics Ltd, on October 20, 2020.